Anthony R. Mato
About
Anthony R. Mato is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics.
According to data from OpenAlex, Anthony R. Mato has authored 85 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pathology and Forensic Medicine, 36 papers in Oncology and 32 papers in Genetics. Recurrent topics in Anthony R. Mato's work include Lymphoma Diagnosis and Treatment (56 papers), Chronic Lymphocytic Leukemia Research (31 papers) and CAR-T cell therapy research (18 papers). Anthony R. Mato is often cited by papers focused on Lymphoma Diagnosis and Treatment (56 papers), Chronic Lymphocytic Leukemia Research (31 papers) and CAR-T cell therapy research (18 papers). Anthony R. Mato collaborates with scholars based in United States, United Kingdom and Switzerland. Anthony R. Mato's co-authors include Jakub Svoboda, Stephen J. Schuster, Sunita D. Nasta, Daniel J. Landsburg, Elise A. Chong, Simon F. Lacey, Carl H. June, Bruce L. Levine, J. Joseph Melenhorst and David L. Porter and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Anthony R. Mato
82 papers receiving 2.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Anthony R. Mato United States | 24 | 1.9k | 1.1k | 746 | 632 | 619 | 85 | 2.8k | ||
| Tanya Siddiqi United States | 29 | 2.5k 1.3× | 1.6k 1.5× | 1.0k 1.4× | 655 1.0× | 777 1.3× | 205 | 3.5k | ||
| Saad S. Kenderian United States | 25 | 2.1k 1.1× | 527 0.5× | 559 0.7× | 737 1.2× | 790 1.3× | 149 | 2.9k | ||
| Lihua E. Budde United States | 25 | 3.0k 1.5× | 1.1k 1.1× | 388 0.5× | 734 1.2× | 917 1.5× | 160 | 3.4k | ||
| Timothy S. Fenske United States | 27 | 1.7k 0.9× | 1.2k 1.2× | 624 0.8× | 435 0.7× | 522 0.8× | 162 | 2.6k | ||
| Elise A. Chong United States | 16 | 2.1k 1.1× | 711 0.7× | 285 0.4× | 509 0.8× | 638 1.0× | 110 | 2.5k | ||
| Alex F. Herrera United States | 28 | 2.5k 1.3× | 2.1k 2.0× | 587 0.8× | 392 0.6× | 642 1.0× | 239 | 3.5k | ||
| Paolo Strati United States | 29 | 961 0.5× | 906 0.9× | 1.1k 1.5× | 539 0.9× | 632 1.0× | 141 | 2.5k | ||
| Javier Muñoz United States | 23 | 1.2k 0.6× | 886 0.8× | 545 0.7× | 357 0.6× | 333 0.5× | 133 | 1.8k | ||
| Paolo F. Caimi United States | 23 | 1.5k 0.8× | 948 0.9× | 423 0.6× | 467 0.7× | 387 0.6× | 209 | 2.2k | ||
| Olalekan O. Oluwole United States | 25 | 2.1k 1.1× | 498 0.5× | 123 0.2× | 604 1.0× | 508 0.8× | 154 | 2.4k |
Countries citing papers authored by Anthony R. Mato
Since
Specialization
Citations
This map shows the geographic impact of Anthony R. Mato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony R. Mato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony R. Mato more than expected).
Fields of papers citing papers by Anthony R. Mato
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Anthony R. Mato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony R. Mato. The network helps show where Anthony R. Mato may publish in the future.
Co-authorship network of co-authors of Anthony R. Mato
This figure shows the co-authorship network connecting the top 25 collaborators of Anthony R. Mato. A scholar is included among the top collaborators of Anthony R. Mato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony R. Mato. Anthony R. Mato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Shah, Nirav N., Anikó Szabó, Raya Saba, et al.. (2018). Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. Clinical Lymphoma Myeloma & Leukemia. 19(2). 95–102.
2.
Jones, Jeffrey A., Anthony R. Mato, Steven Coutré, et al.. (2018). Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials. British Journal of Haematology. 182(4). 504–512.
3.
Bair, Steven M., Anthony R. Mato, & Jakub Svoboda. (2018). Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. Clinical Lymphoma Myeloma & Leukemia. 18(6). 380–391.
4.
Sargent, Rachel L., Sunita D. Nasta, Jakub Svoboda, et al.. (2018). Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non–Burkitt Aggressive B-cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 18(10). 673–678.
5.
Nabhan, Chadi & Anthony R. Mato. (2017). Emerging Strategies in Treating Double Hit Lymphomas. Clinical Lymphoma Myeloma & Leukemia. 17(9). 563–568.
6.
Chong, Elise A., J. Joseph Melenhorst, Jakub Svoboda, et al.. (2017). Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy. Blood. 130. 4121–4121.
7.
Svoboda, Jakub, Daniel J. Landsburg, Sunita D. Nasta, et al.. (2017). Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial. Blood. 130. 191–191.
8.
Chong, Elise A., Tahamtan Ahmadi, Nicole A. Aqui, et al.. (2015). Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas. Clinical Cancer Research. 21(8). 1835–1842.
9.
Howlett, Christina, Sonya J. Snedecor, Daniel J. Landsburg, et al.. (2015). Front‐line, dose‐escalated immunochemotherapy is associated with a significant progression‐free survival advantage in patients with double‐hit lymphomas: a systematic review and meta‐analysis. British Journal of Haematology. 170(4). 504–514.
10.
Gopal, Ajay K., Stefano Tarantolo, Naresh Bellam, et al.. (2014). Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Investigational New Drugs. 32(6). 1213–1225.
11.
Wang, Kai, Michelle Nahas, Roman Yelensky, et al.. (2014). Novel Chromatin Modifying Gene Alterations and Significant Survival Association of ATM and P53 in Mantle Cell Lymphoma. Blood. 124(21). 3033–3033.
12.
Donato, Michèle L., Themba Nyirenda, David H. Vesole, et al.. (2013). Donor CD3 Chimerism After Allogeneic Transplantation Predicts Probability Of Relapse For Patients Treated For Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Non-Hodkgin's Lymphoma (NHL). Blood. 122(21). 4545–4545.
13.
Feldman, Tatyana, Kar Fai Chow, Anthony R. Mato, et al.. (2013). PEG-Asparaginase Based Multidrug Chemotherapy is Effective for Refractory Disseminated Extranodal NK/T-Cell Lymphoma With Leptomentigeal Involvement: A Clinical Case Report and Review of Literature. 2(1). 31–36.
14.
Houldsworth, Jane, Asha Guttapalli, Venkata J. Thodima, et al.. (2013). Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. Leukemia & lymphoma. 55(4). 920–928.
15.
Rowley, Scott D., Stuart L. Goldberg, Anthony R. Mato, et al.. (2012). Decitabine Plus Mini Fludarabine and Busulfan Yields Durable Engraftment with Low Relapse Rates in Elderly or Medically Infirm Patients with Myeloid Malignancies. Blood. 120(21). 1936–1936.
16.
Mato, Anthony R., James A Greenberg, Mary Putt, et al.. (2012). Baseline Serum Cytokines Profiles in Mantle Cell Lymphoma Correlates with Outcome. Blood. 120(21). 1579–1579.
17.
Mato, Anthony R. & André Goy. (2012). Role of Positron Emission Tomography with Fludeoxyglucose F 18 in Personalization of Therapy in Patients with Lymphoma. PET Clinics. 7(1). 57–65.
18.
Feldman, Tatyana, Anthony R. Mato, Aisha Masood, et al.. (2010). Effect of front-line therapy with either high-dose therapy and autologous stem cell rescue (HDT/ASCR) or dose-intensive therapy (R-Hypercvad) on outcome in mantle cell lymphoma (MCL).. Journal of Clinical Oncology. 28(15_suppl). 8067–8067.
19.
Tsai, Donald E., Selina M. Luger, Charalambos Andreadis, et al.. (2008). A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia. Clinical Cancer Research. 14(17). 5619–5625.
20.
Mato, Anthony R., Andrea Miltiades, Daniel F. Heitjan, et al.. (2006). Reproducibility of the Penn predictive score of tumor lysis syndrome (PPS-TLS) in acute myelogenous leukemia (AML). Journal of Clinical Oncology. 24(18_suppl). 6577–6577.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Tanya Siddiqi Breakdown of academic impact, for papers by Saad S. Kenderian Breakdown of academic impact, for papers by Lihua E. Budde Breakdown of academic impact, for papers by Timothy S. Fenske Breakdown of academic impact, for papers by Elise A. Chong Breakdown of academic impact, for papers by Alex F. Herrera Breakdown of academic impact, for papers by Paolo Strati Breakdown of academic impact, for papers by Javier Muñoz Breakdown of academic impact, for papers by Paolo F. Caimi Breakdown of academic impact, for papers by Olalekan O. Oluwole